Derm-Biome gears up for skin rejuvenation trial in 2022

Canadian skin rejuvenation start-up also spawns longevity biopharma company targeting inflammatory cytokines.

Longevity.Technology is growing fast; we are open to conversations with prospective partners and investors who share our vision.

Please get in touch if you are interested:

Canadian skin rejuvenation start-up also spawns longevity biopharma company targeting inflammatory cytokines.

Vancouver-based Derm-Biome Pharmaceuticals and its sister company, Pan-Biome Pharmaceuticals, are developing novel, natural product-based compounds focused on targeting the chronic inflammation that is linked to many age-related diseases of aging and, indeed, the aging process itself. As its name suggests, Derm-Biome’s focus is on diseases of the skin, and the company is preparing to run a Phase I clinical trial in humans next year to investigate the safety, tolerability and efficacy of its compound on skin hydration and rejuvenation in a healthy adult population.

Create a free account to read this article now

Join the 12,000+ biotech, pharma and investment leaders who read Longevity.Technology. No password, no payment.

By continuing you agree to our Terms and Privacy Policy, and to receive the free Longevity.Technology newsletter. You can unsubscribe at any time.

Danny Sullivan

Danny has worked in technology communications for more than 20 years, and has been writing about developments the longevity sector since 2019. With a keen interest in the transfer of technology to market, he focuses primarily on the companies working on cutting-edge solutions to aging and age-related diseases.

Sign up for our daily newsletter to get our biggest longevity stories, handpicked for you each day.

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE